// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























2187 Abstracts

Comparison of RIC-alloHCT and autoHCT for >55 years old patients with acute lymphoblastic leukemia: an analysis from Acute Leukemia Working Party of the EBMT

S. Giebel - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Effectiveness of preventive parenteral nutrition enriched with high glutamine and omega-3 fatty acids in allogeneic stem cell transplantation

M. Kucher - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Hydroxyzine

Donor lymphocyte infusion (DLI) as salvage treatment for refractory or relapsed lymphoid malignancies after allogeneic stem cell transplantation: Experience from a single centre.

G. Martin Sanchez - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

N/A

Comparison of The Adverse Reactions Due to Hematopoietic Stem Cell Infusion Between The Patients Younger Than And Elder Than 60 Years Old

N. Baskan - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

DMSO

Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces non-relapse mortality

A. Mancusi - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

N/A

Hematopoietic Stem Cell Transplantation in Children Using Preimplantation Genetic Diagnosis for HLA-Matched Donor: a Turkish Multicenter Study

A. E. Kuerekci - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

Extracorporeal Photopheresis (ECP) As Second Line Treatment For Refractory Graft Versus Host Disease (GVHD): Preliminary Single Centre Experience.

M. Gonzalez-Pardo - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Mycophenolate mofetil

Multipotent mesenchimal stromal cells as graft-versus-host disease prophylaxis: a prospective randomised clinical trial

L. Kuzmina - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Mycophenolate mofetil

Incidence and outcome of infections after unrelated cord blood transplantation in patients with hematological malignancies: a long-term single center experience.

E. Scalzulli - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Ciprofloxacin

Effect of pretransplant body mass index on the clinical outcome after allogeneic stem cell transplantation in patients with hematologic malignancies : a single center experience

A. Gokmen - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acute lymphoblastic leukemia

N/A

Low incidence of veno-occlusive disease after using intravenous busulfan in allogenic hematpoietic stem cell transplantation for acute lymphoblastic leukemia

M. Ramzi - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Busulfan

Donor KIR A haplotype is associated with an increased in T cell recovery after DLI and better overall survival after HLA match sibling pediatric stem cell transplantation

A. Perez Martnez - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Allogeneic hematopoietic stem cell transplantation for pediatric T lineage acute lymphoblastic leukemia

H. Sakaguchi - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Busulfan

Encouraging results of reduced-intensity allogeneic haematopoietic stem cell transplantation for paediatric patients with acute lymphoblastic leukemia in second complete remission

K. Higuchi - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

BID, BAK AND BCL-XL expression in childhood acute lymphoblastic leukemia bone marrow

M. Panagouli - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Allogeneic transplantation for acute lymphoblastic leukemia (ALL) in adults 2008-2013: results from Denmark.

I. Schjoedt - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Mycophenolate mofetil

TCR??+/CD19+-depletion in hematopoietic stem cells transplantation from matched unrelated and haploidentical donors following treosulfan-based conditioning in pediatric acute lymphoblastic leukemia patients.

L. Shelikhova - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Thymoglobuline

A pilot study of post-transplant hypomethylating agents + Bortezomib + NK/gamma-delta T cell infusions in children with hematological malignancies

M. Ilushina - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Thymoglobuline

Autologous peripheral blood stem cell transplantation in poor mobilizer patients

R. Perez-Lopez - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Autologous peripheral blood stem cell transplantation in very poor mobilizer patients

R. Perez-Lopez - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Copyright © 2026. QuantiNova All rights reserved